BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data
An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.
BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data Read More »
